Status:
COMPLETED
Vascular Complications and Bleeding After Transfemoral TAVI
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Severe and Symptomatic Aortic Stenosis
Undergoing TAVI
Eligibility:
All Genders
18+ years
Brief Summary
Since the first implantation by Cribier, transcatheter aortic valve implantation (TAVI) revolutionized the management of severe symptomatic aortic stenosis. Indeed, TAVI is indicated as an alternative...
Detailed Description
This prospective monocentric observational study aims to include all patients undergoing TAVI via transfemoral access from November 2017 at Montpellier University Hospital, France. All procedures are...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients undergoing a TAVI at Montpellier University Hospital
- Since November 2017
- With implantation of a COREVALVE or EDWARDS
- By femoral approach
- Exclusion criteria:
- Minor patient
- Patient unable to give consent for reasons of understanding or language barrier
Exclusion
Key Trial Info
Start Date :
February 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03865043
Start Date
February 1 2019
End Date
December 31 2019
Last Update
March 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uhmontpellier
Montpellier, France, 34295